EW 8-K Current Reports
Edwards Lifesciences Corp - 203 current reports
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 8, 2026)
Edwards Lifesciences Corporation (EW) held its Annual Meeting of Stockholders on May 7, 2026, where key proposals related to executive compensation and corporate governance were voted upon. The most significant outcome for investors is the approval of the Amended and Restated Long-Term Stock Incentive Compensation Program. This program amendment includes an increase of 7,000,000 shares available for issuance, bringing the total to 341,500,000 shares. This expansion of the equity pool is crucial for future employee and executive compensation, potentially influencing long-term shareholder value through incentive alignment. Additionally, all director nominees were elected, and stockholders approved the advisory proposal on executive compensation and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The overwhelming approval of these proposals suggests continued confidence from shareholders in the company's leadership, compensation strategies, and financial oversight.
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 4, 2026)
Edwards Lifesciences Corporation (EW) has announced a significant leadership change in its finance department, appointing Theodora Mistras as its new Corporate Vice President, Chief Financial Officer, effective May 29, 2026. Ms. Mistras succeeds Scott B. Ullem and brings a strong background in healthcare investment banking from her previous roles at Citigroup and Goldman Sachs, as well as her recent experience as CFO of Viatris, Inc. This appointment signals a potential strategic focus on financial operations and capital allocation under new leadership. Investors should note the comprehensive compensation package, including a substantial base salary, bonus potential, a significant sign-on bonus, and substantial equity awards, which underscores the company's investment in securing experienced financial leadership. The new CFO's compensation package includes an annual base salary of $925,000, a target annual bonus of at least 100% of base salary, a $2,013,000 sign-on bonus, and an initial restricted stock unit (RSU) grant valued at $8,000,000. Future annual equity awards are also planned, with a $4,500,000 grant date value for fiscal year 2026. This structure indicates a strong emphasis on aligning Ms. Mistras's incentives with the company's long-term performance and shareholder value. The company has also provided severance protections and relocation assistance, demonstrating a commitment to supporting its new executive through the transition.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 23, 2026)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on April 23, 2026, primarily to disclose its financial results for the first quarter of 2026 via an attached press release. While the 8-K itself doesn't provide granular details, it signals that investors can now access the company's performance metrics for the initial quarter of the year. This includes key financial data such as revenue, earnings per share, and potentially other operational highlights relevant to their cardiovascular and critical care devices business. Investors should carefully review the furnished press release (Exhibit 99.1) for a comprehensive understanding of EW's Q1 2026 performance. This will offer insights into the company's growth trajectory, profitability, and any forward-looking guidance or commentary provided by management. The filing indicates that the company met its reporting obligations for the period, allowing the market to assess its progress against expectations and industry trends.
Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 10, 2026)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 10, 2026, to announce its financial results for the fourth quarter of 2025. While the 8-K itself is brief and primarily serves to incorporate the details from a furnished press release (Exhibit 99.1), the core information pertains to the company's performance in the latest reported quarter. Investors should review the accompanying press release for specific figures on revenue, profitability, and any forward-looking guidance provided by the company.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
Edwards Lifesciences Corporation (EW) announced on January 11, 2026, that its proposed acquisition of JenaValve Technology, Inc. has been blocked by a preliminary injunction granted by the U.S. District Court for the District of Columbia at the request of the U.S. Federal Trade Commission (FTC). Consequently, the transaction will not proceed as planned. This development is a significant setback for Edwards Lifesciences' strategic growth initiatives and integration plans that hinged on the acquisition of JenaValve. Investors should focus on the implications of this failed acquisition, including potential impacts on future revenue streams, market positioning, and the company's capital allocation strategy. While the financial terms of the deal and any termination fees are not detailed in this 8-K, this event signifies a need for management to reassess its inorganic growth strategy and potentially seek alternative avenues for market expansion or product portfolio enhancement. The company's stock performance may be influenced by market reaction to this news and any subsequent management commentary.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 30, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on October 30, 2025, to disclose its financial results for the third quarter of 2025. The report primarily references a press release, dated October 30, 2025, which contains the detailed financial outcomes for the period. Investors should refer to this press release (Exhibit 99.1) for comprehensive information regarding the company's performance, including revenue, profitability, and any key operational metrics. This filing serves as notification of these results and does not represent new financial statements being filed directly within the 8-K. The furnished information under Item 2.02, including the press release, is not considered 'filed' for the purposes of the Securities Exchange Act of 1934, meaning the company retains protection against potential liabilities associated with such information until officially filed in subsequent reports. Investors are encouraged to review the press release for a full understanding of the company's third-quarter performance.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Oct 30, 2025)
Edwards Lifesciences Corporation (EW) announced a significant leadership change via an 8-K filing on October 30, 2025. Chief Financial Officer (CFO) Scott Ullem has informed the company of his decision to transition out of his role by mid-2026. This development triggers an active search for a successor to lead the company's financial strategy. While the departure is planned for mid-2026, the immediate focus for investors is the initiation of the CFO selection process. This transition, though not immediate, is a key event that warrants attention as the company navigates its financial future. Investors will be keen to understand the timeline for appointing a new CFO and the potential impact on the company's financial management and strategic direction.
Edwards Lifesciences Corp 8-K Report, Corporate Update (Aug 19, 2025)
Edwards Lifesciences Corporation (EW) has announced its entry into an accelerated share repurchase (ASR) agreement, as detailed in an 8-K filing dated August 19, 2025. This strategic move indicates the company's commitment to returning capital to shareholders and reflects management's confidence in the company's financial health and future prospects. Investors should note that ASR agreements typically involve repurchasing a significant amount of stock in a short period, which can positively impact earnings per share and signal a belief by the company that its stock is undervalued. The press release filed as Exhibit 99.1 provides further details on the terms and expected impact of this repurchase program.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Aug 6, 2025)
Edwards Lifesciences Corporation (EW) has announced a significant development regarding its proposed acquisition of JenaValve Technology, Inc. In a press release issued on August 6, 2025, the company disclosed that the U.S. Federal Trade Commission (FTC) has initiated action to block this acquisition. This news represents a key event for the company and its investors, potentially impacting strategic growth plans and financial outlook. While the specifics of the FTC's reasoning are not detailed in this 8-K filing, the blocking of the acquisition by a regulatory body signals potential challenges in executing strategic M&A activities. Investors should monitor future communications from Edwards Lifesciences for updates on the company's response to the FTC's decision and any potential alternative strategies for market expansion or technological integration.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Jul 25, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing a significant executive departure. Larry L. Wood, Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart, has resigned to pursue an opportunity outside the cardiovascular industry. Mr. Wood's resignation is effective September 1, 2025. This change in leadership, particularly within the TAVR segment, is a key development for investors to monitor. While the departure is for a non-competitive reason, the transition of responsibilities will be crucial. Daniel J. Lippis, currently overseeing key Asian markets, will assume leadership for the TAVR business unit. Investors should assess the company's communication regarding the strategic implications of this transition and Mr. Lippis's ability to drive the TAVR segment forward.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 24, 2025)
Edwards Lifesciences Corp (EW) has filed a Form 8-K reporting its financial results for the second quarter of 2025, as of July 23, 2025. The primary focus of this filing is the issuance of a press release detailing the company's performance during the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial figures, including revenue, earnings per share, and any commentary on operational performance and outlook. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the release of this information. The press release is expected to provide insights into key growth drivers, segment performance (such as transcatheter aortic valve replacement - TAVR, and critical care), and any forward-looking guidance provided by the company. Investors should carefully review Exhibit 99.1 for a comprehensive understanding of Edwards Lifesciences' recent financial health and future expectations.
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 8, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing the outcomes of its 2025 Annual Meeting of Stockholders. The primary financial information relevant to investors concerns the approval of amendments to the company's Employee Stock Purchase Plans (ESPPs). Stockholders overwhelmingly approved the amendment and restatement of both the U.S. ESPP and the International ESPP, significantly increasing the number of shares available for issuance under these plans. This move indicates a continued commitment to employee stock ownership and may signal management's anticipation of future stock price appreciation, as more shares will be available for purchase by employees at potentially favorable prices.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 23, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on April 23, 2025, announcing its financial results for the first quarter of 2025. The primary driver of this filing is the press release furnished as Exhibit 99.1, which details the company's performance during the period ending April 22, 2025. Investors should refer to this press release for specific financial metrics, including revenue, profitability, and any forward-looking guidance provided by the company.
Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 11, 2025)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 11, 2025, to announce its fourth quarter 2024 financial results. The primary purpose of this filing is to provide investors with the official release of the company's performance metrics for the period ending December 31, 2024. This report serves as the primary source for detailed financial outcomes, including revenue, profitability, and other key operational indicators that shape the company's current financial standing. Investors should pay close attention to the press release, furnished as Exhibit 99.1, which contains the comprehensive financial details for the fourth quarter of 2024. While this 8-K filing itself does not contain the detailed financial statements, it directs stakeholders to the official press release for these critical figures. The information provided in this release will be instrumental in assessing the company's recent performance and its implications for future financial health and strategic direction.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 24, 2024)
Edwards Lifesciences Corporation (EW) has filed a Form 8-K to report its financial results for the third quarter of 2024, as detailed in a press release dated October 24, 2024. While the filing itself is brief and primarily serves to incorporate the press release, the information contained within that release is crucial for investors to understand the company's recent performance and financial condition. Investors should focus on the details within the furnished press release (Exhibit 99.1) for specific figures regarding revenue, profitability, and any forward-looking guidance. This 8-K signals the official release of Q3 2024 earnings and provides the foundational data upon which further analysis of the company's operational success and strategic direction can be built. The filing itself does not contain new financial statements or operational commentary beyond referencing the press release.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Sep 3, 2024)
Edwards Lifesciences Corporation (EW) announced the completion of the sale of its Critical Care product group to Becton, Dickinson and Company on September 3, 2024. This divestiture marks a significant strategic shift for Edwards, allowing it to focus more intently on its core cardiovascular businesses. Investors should note that this transaction is expected to reshape the company's operational and financial profile moving forward. Concurrently, the company's Board of Directors approved a substantial $1.5 billion increase in its share repurchase authorization, alongside entering into a $500 million accelerated share repurchase agreement. These capital allocation decisions signal a strong commitment to returning value to shareholders and reflect management's confidence in the company's future prospects and financial flexibility post-divestiture. Investors will want to monitor how these buyback programs are executed and their impact on EPS.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 24, 2024)
Edwards Lifesciences (EW) has filed an 8-K report detailing significant corporate developments beyond its second-quarter 2024 financial results. The company announced two strategic acquisitions: JenaValve Technology, Inc., a company focused on transcatheter treatment of aortic regurgitation, and Endotronix, Inc., known for its FDA-approved Cordella Sensor for pulmonary artery pressure monitoring. These acquisitions represent a substantial investment, with an upfront cash payment of approximately $1.2 billion and potential additional milestone payments of up to $445 million. The strategic rationale appears to be strengthening Edwards' position in the structural heart disease market and expanding its portfolio of innovative medical devices. While the 8-K incorporates the press release detailing Q2 2024 financial results (Exhibit 99.1), the primary focus of the filing for investors is the news of these two significant acquisitions. The acquisitions are subject to customary closing conditions, and the company has provided forward-looking statements outlining potential risks and uncertainties associated with their completion and integration. Investors should pay close attention to the closing status and future performance contributions of these newly acquired entities.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jul 15, 2024)
Edwards Lifesciences Corporation (EW) announced on July 15, 2024, that it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage company focused on transcatheter mitral valve replacement (TMVR) technology. This strategic move signals EW's intent to bolster its position in the rapidly growing structural heart market, particularly in the complex mitral valve space. The acquisition is expected to close by the end of 2024, with an approximate cash consideration of $300 million. While the financial terms are substantial, the potential to integrate Innovalve's early-stage TMVR technology could represent a significant long-term growth opportunity for Edwards Lifesciences, aligning with its existing portfolio and expertise in minimally invasive cardiac procedures.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Jul 10, 2024)
Edwards Lifesciences Corporation (EW) has announced a significant addition to its Board of Directors with the appointment of David T. Feinberg, M.D., effective immediately. Dr. Feinberg brings a wealth of experience spanning nearly three decades in health system management and health information technology services. His extensive background includes leadership roles at prominent organizations such as Oracle Health (Chairman), Cerner Corporation (CEO), Google Health (Vice President), and Geisinger Health (President and CEO), as well as significant experience within UCLA Health. This appointment is particularly noteworthy given Dr. Feinberg's deep expertise in healthcare operations, technology, and quality improvement, which are highly relevant to Edwards Lifesciences' mission in advanced medical technologies. His role as a member of the Board's Audit Committee will further enhance the board's oversight capabilities. Investors may view this as a positive development, signaling a continued focus on strategic growth and operational excellence within the company.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Jun 17, 2024)
Edwards Lifesciences Corp (EW) announced a key leadership change within its finance department. Robert W.A. Sellers, the current Senior Vice President and Principal Accounting Officer, will retire effective July 1, 2024. This retirement marks the end of Mr. Sellers' tenure, and the company has promptly named his successor. Andrew M. Dahl, who joined Edwards in February 2024 as Senior Vice President and Corporate Controller, will step into the role of Principal Accounting Officer upon Mr. Sellers' retirement. Mr. Dahl brings a wealth of experience from his previous roles at Medtronic PLC, Polaris Industries, and Deloitte & Touche LLP, including extensive background in financial reporting and controls. The company has confirmed that Mr. Dahl's appointment is standard and he has no material business relationships or family ties that would require disclosure under SEC regulations.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jun 3, 2024)
Edwards Lifesciences Corporation (EW) has announced a significant strategic shift via an 8-K filing on June 3, 2024. The company has entered into a Stock and Asset Purchase Agreement to sell its Critical Care product group to Becton, Dickinson and Company for $4.2 billion in cash. This divestiture represents a major change in the company's portfolio and is a substantial cash inflow. In conjunction with this sale, Edwards Lifesciences has also announced it is abandoning its previously planned spin-off of the Critical Care business. Investors should focus on the strategic implications of this sale, the use of proceeds from the $4.2 billion transaction, and how this will shape the future direction of Edwards Lifesciences, particularly its core structural heart and critical care businesses. The filing also includes forward-looking statements detailing potential risks and uncertainties related to the closing of the transaction.
Edwards Lifesciences Corp 8-K Report, Shareholder Vote Results (May 8, 2024)
Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing the results of its Annual Meeting of Stockholders held on May 7, 2024. The filing confirms the election of all director nominees, with substantial support from shareholders. Additionally, shareholders provided advisory approval for the company's executive compensation, ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approved the Amended and Restated Long-Term Stock Incentive Compensation Program. These outcomes indicate strong shareholder confidence in the company's leadership, financial oversight, and long-term incentive structures. For investors, the overwhelming support for director nominees and the approval of key proposals signal stability and alignment between management and the shareholder base. The ratification of the auditor and the incentive program are routine but important votes that maintain operational continuity and provide a framework for future executive performance and retention. The minimal 'against' votes on these matters, particularly executive compensation and the incentive program, suggest that current shareholder concerns, if any, are not widespread or are being addressed through other company communications.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 25, 2024)
Edwards Lifesciences Corporation (EW) filed an 8-K on April 24, 2024, to report its financial results for the first quarter of 2024. The press release, furnished as an exhibit, details the company's performance during the period. Investors should note that this filing primarily serves to disseminate the Q1 2024 earnings information and does not contain new operational or strategic developments beyond what is presented in the earnings release. The core of this report is the Q1 2024 financial performance. While the filing itself does not provide the detailed numbers, it directs investors to the press release (Exhibit 99.1) for specific revenue, profitability, and other key financial metrics. Investors are encouraged to review the furnished press release for a comprehensive understanding of Edwards Lifesciences' recent financial standing and operational results.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Mar 26, 2024)
Edwards Lifesciences Corporation (EW) announced significant changes to its Board of Directors, effective in conjunction with the upcoming 2024 Annual Meeting of Stockholders on May 7, 2024. Most notably, Michael A. Mussallem, the current Non-Executive Chairman, has decided to retire from his position and will not seek re-election to the Board. This marks the end of a long tenure for Mr. Mussallem, who has been instrumental in the company's leadership.
Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 6, 2024)
Edwards Lifesciences Corporation (EW) filed an 8-K on February 6, 2024, to announce its fourth-quarter 2023 financial results. While the filing itself is brief and primarily references an attached press release (Exhibit 99.1), the core information relates to the company's performance during the last quarter of 2023. Investors should review the furnished press release for detailed financial figures, including revenue, earnings per share, and any forward-looking guidance provided by management. This report serves as the official channel for disclosing these key financial metrics, which are crucial for assessing the company's operational success, profitability, and overall financial health. The filing indicates that the detailed results and commentary are available in the press release, making it the primary source for understanding EW's recent financial standing and future outlook.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Dec 7, 2023)
Edwards Lifesciences Corporation (EW) announced a significant strategic shift at its 2023 Investor Conference, detailing plans to spin off its Critical Care product group by the end of 2024. This move is intended to be a tax-free transaction, allowing the company to focus on its core transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) businesses, while the Critical Care segment will operate as an independent entity. Investors should note that further details regarding the spin-off, including a Form 10 filing with the SEC, are anticipated in mid-2024. In addition to the strategic spin-off, the company's Board of Directors has approved an additional $1 billion in share repurchase authorization. This signals continued confidence in the company's financial health and commitment to returning capital to shareholders. The spin-off is expected to unlock value and allow for more focused capital allocation and strategic growth opportunities for both the remaining Edwards Lifesciences and the new independent Critical Care company.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 25, 2023)
Edwards Lifesciences Corporation (EW) filed an 8-K on October 25, 2023, primarily to report its financial results for the third quarter of 2023. While the 8-K itself is brief and refers to an attached press release (Exhibit 99.1) for the detailed financial information, investors should focus on the content of that press release for performance insights. This filing signals the release of Q3 2023 earnings, which is a critical update on the company's operational and financial health.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 26, 2023)
Edwards Lifesciences Corporation (EW) filed an 8-K on July 26, 2023, announcing its financial results for the second quarter of 2023. The primary purpose of this filing is to provide investors with the company's performance metrics for the period. While the 8-K itself is brief, it references an attached press release (Exhibit 99.1) which contains the detailed financial results, including key performance indicators and operational updates. Investors should refer to the furnished press release for comprehensive details on revenue, earnings, and any forward-looking statements or business segment performance. This filing serves as official notification and dissemination of this important quarterly information, ensuring transparency for shareholders and the market. The information provided is crucial for assessing the company's current financial health and future prospects.
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 15, 2023)
This 8-K filing from Edwards Lifesciences (EW) details several key events that occurred around their 2023 Annual Meeting of Stockholders on May 10th, 2023. Most notably, the company announced an increase in CEO Bernard J. Zovighian's annual base salary to $1,050,000 and an incentive pay target of $1,470,000. This compensation adjustment reflects his prior appointment as Chief Executive Officer. Furthermore, the filing reports on the outcomes of various shareholder proposals. All director nominees were elected, and shareholders approved the company's executive compensation on an advisory basis, favoring annual "say-on-pay" votes. A significant amendment to the company's Certificate of Incorporation to provide exculpation for officers, as permitted by Delaware law, was also approved by stockholders. However, a shareholder proposal requesting an independent board chairman policy was not approved. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 was also ratified.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 26, 2023)
Edwards Lifesciences Corporation (EW) filed an 8-K on April 25, 2023, to report its financial results for the first quarter of 2023. The key information is contained within the press release (Exhibit 99.1) attached to this filing, which details the company's performance and financial condition as of and for the period ending in Q1 2023. Investors should review this press release for specific revenue, earnings, and any forward-looking guidance provided. While the 8-K itself is brief, it signifies the official release of quarterly financial data. The attached press release will offer a comprehensive overview of how Edwards Lifesciences performed against expectations, any significant operational updates, and management's outlook for the remainder of the fiscal year. This is a crucial report for understanding the company's current trajectory and making informed investment decisions.
Edwards Lifesciences Corp 8-K Report, Bylaw Amendment (Feb 21, 2023)
Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing amendments to its Bylaws, primarily related to director nominations and corporate governance. These changes, effective February 16, 2023, aim to align the company's procedures with new universal proxy rules (Rule 14a-19) and enhance the disclosure requirements for shareholder nominations. The amendments seek to provide greater clarity and robustness to the director nomination process, ensuring compliance and facilitating shareholder engagement within a structured framework. For investors, these updates signify a proactive approach by Edwards Lifesciences to modernize its governance practices. The incorporation of universal proxy rules and enhanced informational requirements for director nominees are designed to ensure a more efficient and transparent shareholder meeting process. While these changes do not directly impact the company's financial performance or strategic operations, they are crucial for maintaining good corporate governance, which can indirectly influence investor confidence and long-term shareholder value.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jan 31, 2023)
Edwards Lifesciences Corporation (EW) filed an 8-K on January 31, 2023, to announce its fourth-quarter 2022 financial results. This report primarily serves to furnish a press release containing the company's performance for the period ending December 31, 2022. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial figures and operational updates. The 8-K itself does not provide new quantitative financial data but directs stakeholders to the press release for the specifics of the Q4 2022 performance. Therefore, an analysis of the actual financial results and their implications requires a review of the accompanying press release, which covers topics such as sales, earnings, and any forward-looking guidance the company may have provided.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Dec 8, 2022)
Edwards Lifesciences Corporation (EW) announced a significant leadership transition, with current CEO Michael A. Mussallem planning to retire from his CEO role at the company's Annual Meeting of Stockholders on May 11, 2023. Mr. Mussallem will transition to a non-executive Chairman of the Board position, ensuring continued strategic guidance. Bernard J. Zovighian, currently corporate vice president and general manager for the Transcatheter Mitral and Tricuspid Therapies (TMTT) business, has been appointed President effective January 1, 2023, and will succeed Mr. Mussallem as CEO on May 11, 2023. This planned succession aims to provide continuity and leverage Mr. Zovighian's extensive experience, particularly in the TMTT segment, which is a key growth area for Edwards. The company also announced compensation adjustments for Mr. Zovighian and Larry Wood, who is taking on an expanded role. These changes are part of a strategic move to position the company for future growth and innovation under new leadership, while retaining valuable experience at the board level.
Edwards Lifesciences Corp 8-K Report, Corporate Update (Nov 1, 2022)
Edwards Lifesciences Corporation (EW) announced on November 1, 2022, its entry into an Accelerated Share Repurchase Agreement (ASR). This move signifies management's confidence in the company's stock and its commitment to returning capital to shareholders. While the specific details of the ASR agreement, such as the total dollar amount or the number of shares to be repurchased, are not fully detailed in this 8-K filing itself, the press release incorporated by reference likely provides these crucial figures. Investors should review the associated press release for a comprehensive understanding of the share repurchase program's scope and potential impact on the company's financials and stock valuation.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 27, 2022)
Edwards Lifesciences (EW) filed an 8-K on October 27, 2022, to announce its financial results for the third quarter of 2022. The filing primarily consists of a press release that details the company's performance during the period. Investors should pay close attention to the revenue, earnings per share, and any forward-looking guidance provided in the press release for a comprehensive understanding of the company's current financial health and future outlook.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 28, 2022)
Edwards Lifesciences Corporation (EW) filed an 8-K on July 27, 2022, to announce its financial results for the second quarter of 2022. The report primarily references a press release issued on July 28, 2022, which contains the detailed financial outcomes for the quarter. Investors should refer to this press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company.
Edwards Lifesciences Corp 8-K Report, Material Agreement (Jul 21, 2022)
Edwards Lifesciences Corporation (EW) announced on July 20, 2022, its entry into a new five-year credit agreement, effective July 15, 2022. This agreement establishes a $750 million multi-currency unsecured revolving credit facility, replacing the company's previous 2018 credit agreement. The new facility offers improved pricing and terms compared to its predecessor. The company has the option to increase the facility size by an additional $250 million, subject to lender approval. Borrowings under the new revolving facility will be subject to variable interest rates tied to the Secured Overnight Financing Rate (SOFR) or a base rate, plus an applicable margin based on leverage or debt ratings. The facility matures on July 15, 2027, and is intended for general corporate purposes, with no amounts borrowed as of the filing date. The agreement includes customary covenants and financial restrictions, such as a maximum leverage ratio.
Edwards Lifesciences Corp 8-K Report, Shareholder Vote Results (May 4, 2022)
Edwards Lifesciences Corporation (EW) filed an 8-K on May 4, 2022, detailing the results of its 2022 Annual Meeting of Stockholders held on May 3, 2022. The meeting's primary focus was on shareholder votes regarding director elections, executive compensation, auditor ratification, and a shareholder proposal. All incumbent directors were overwhelmingly re-elected, indicating strong shareholder confidence in the current board's leadership and strategy. Similarly, the advisory vote on executive compensation received majority approval, suggesting alignment between shareholder and management views on compensation practices. The ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, also passed with substantial support. This signifies continued trust in the company's financial reporting and audit processes. However, a shareholder proposal to lower the ownership threshold required to call a special meeting was notably not approved, highlighting a divergence in opinion on corporate governance mechanisms related to shareholder activism.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 26, 2022)
Edwards Lifesciences Corporation (EW) filed an 8-K on April 26, 2022, to report its first quarter 2022 financial results. The report itself is brief, primarily referencing an attached press release (Exhibit 99.1) which contains the detailed financial information. Investors should refer to the press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company for the period ending March 31, 2022. The filing indicates that the information furnished is not considered 'filed' under the Securities Exchange Act, meaning it's not subject to the same liabilities as formally filed registration statements, but it is still crucial for understanding the company's recent performance.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jan 26, 2022)
Edwards Lifesciences Corporation (EW) has filed an 8-K report on January 26, 2022, to announce its fourth quarter 2021 financial results. The press release furnishing the detailed results is incorporated by reference, offering investors insight into the company's performance for the period ending December 31, 2021. While specific figures are not detailed within the 8-K itself, the filing indicates that the press release contains crucial information regarding the company's operational and financial condition for the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for quantitative data and management commentary on sales, profitability, and any forward-looking guidance. This report serves as a notification of the release of these results, which are critical for assessing the company's recent trajectory and future outlook. Key areas to scrutinize in the accompanying press release will likely include sales performance across Edwards' various product segments (such as Transcatheter Heart Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, and Critical Care), earnings per share (EPS), and any updates on strategic initiatives or clinical trial progress. Understanding these financial outcomes is paramount for making informed investment decisions regarding Edwards Lifesciences.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 27, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on October 27, 2021, to report its financial results for the third quarter of 2021. The key event detailed in this filing is the issuance of a press release (Exhibit 99.1) containing the company's performance for the quarter ending in September 2021. While the 8-K itself is brief and primarily serves to incorporate the press release by reference, investors should refer to Exhibit 99.1 for detailed financial figures, operational updates, and management commentary. This filing is crucial for investors tracking EW's performance against expectations and its progress in its core markets, particularly in transcatheter aortic valve replacement (TAVR) and critical care. The information provided in the accompanying press release will shed light on sales growth, profitability, and any forward-looking statements or guidance the company may have issued, enabling investors to assess the company's current financial health and future prospects.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 29, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on July 29, 2021, to report its financial results for the second quarter of 2021. The key takeaway from this filing is the issuance of a press release containing the company's performance metrics for the period ending June 30, 2021. While the 8-K itself is a brief document primarily referencing the press release, investors should refer to the furnished Exhibit 99.1 for the detailed financial and operational data.
Edwards Lifesciences Corp 8-K Report, Bylaw Amendment (Jul 15, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on July 15, 2021, to announce amendments to its corporate Bylaws. These changes primarily focus on modernizing meeting procedures and clarifying governance provisions. Key updates include enabling virtual stockholder meetings and electronic delivery of notices and proxies, aligning with recent Delaware law amendments. This offers greater flexibility and accessibility for shareholder participation and communication. Further enhancements address director nominations, allowing only stockholders of record to nominate candidates and clarifying the maximum number of nominees. The Bylaws also refine procedures for meeting adjournments and the signing of stock certificates. Notably, a new exclusive forum provision designates U.S. federal district courts for Securities Act of 1933 litigation, aiming to streamline legal proceedings. These amendments are designed to improve operational efficiency and corporate governance for the company.
Edwards Lifesciences Corp 8-K Report, Executive Changes (May 5, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on May 5, 2021, primarily to report on the outcomes of its Annual Meeting of Stockholders held on May 4, 2021, and a significant update to its capital return strategy. The meeting saw the retirement of Dr. William J. Link from the Board of Directors, with Mr. Nicholas J. Valeriani appointed to chair the Compensation and Governance Committee. Stockholders overwhelmingly approved key proposals, including the amendment and restatement of both the U.S. and International Employee Stock Purchase Plans (ESPPs), increasing the share pool for these programs. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was ratified, and the executive compensation plan received advisory approval. In a move directly impacting shareholder value, the Board of Directors approved an additional $1 billion for share repurchases under the company's existing program. This substantial authorization, with no expiration date, signals management's confidence and commitment to returning capital to shareholders. While certain shareholder proposals regarding director nominations and written consent were not approved, the overall outcome of the meeting and the expanded share repurchase authorization are the most significant points for investors to note from this filing.
Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 20, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on April 20, 2021, primarily to announce its financial results for the first quarter of 2021. The key takeaway for investors is the company's performance during the period, as detailed in the press release furnished as an exhibit. This filing serves as the official communication of their quarterly financial outcomes and strategic updates. Investors should review the press release for specific revenue figures, earnings per share, and any forward-looking guidance provided by the company. While the 8-K itself is brief, it directs stakeholders to the comprehensive press release for detailed financial performance. This includes information on sales growth across their product segments, particularly in transcatheter heart valves (THV) and critical care, and any significant operational developments. Understanding these results is crucial for assessing the company's current trajectory and its potential impact on future stock performance.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jan 27, 2021)
Edwards Lifesciences Corporation (EW) filed an 8-K on January 27, 2021, to report its financial results for the fourth quarter of 2020. The filing itself is brief and primarily serves to incorporate by reference a press release (Exhibit 99.1) that contains the detailed financial information. Investors should refer to this press release for specifics on the company's performance during the quarter.
Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 22, 2020)
Edwards Lifesciences Corporation (EW) filed an 8-K on October 21, 2020, to report its financial results for the third quarter ended October 20, 2020. The core of this filing is the press release (Exhibit 99.1) which provides investors with the company's performance during the quarter. Investors should review this press release for detailed financial metrics, operational updates, and any forward-looking statements or guidance issued by the company.
Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 23, 2020)
Edwards Lifesciences (EW) filed an 8-K on July 23, 2020, to report its financial results for the second quarter of 2020. This filing primarily serves to furnish a press release detailing the company's performance during the period. Investors should refer to the press release (Exhibit 99.1) for specific financial data, including revenue, earnings, and any forward-looking guidance or commentary provided by the company. While the 8-K itself does not contain the detailed financial tables, it formally announces the release of these results, making them accessible to the public. The information within the press release is crucial for understanding the company's operational and financial standing, especially in the context of the prevailing economic conditions of Q2 2020.
Edwards Lifesciences Corp 8-K Report, Executive Changes (Jul 15, 2020)
Edwards Lifesciences Corporation (EW) announced on July 15, 2020, a significant addition to its Board of Directors. Paul A. LaViolette has been appointed to the Board, effective July 13, 2020, and will also serve on the Compensation and Governance Committee. This appointment is a key development for the company's governance structure, bringing potentially new perspectives to its strategic and compensation decisions. Mr. LaViolette's appointment appears routine, with no disclosed arrangements with other parties or material interests in company transactions requiring specific disclosure. He will be compensated according to the standard director compensation policy, as outlined in the company's prior filings, and will receive the standard indemnification agreement. Investors should note this as a governance update that could influence future board oversight and strategy.
Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Jul 13, 2020)
Edwards Lifesciences Corporation (EW) announced a significant settlement with Abbott Laboratories on July 13, 2020, to resolve all ongoing patent disputes related to transcatheter mitral and tricuspid repair products. This agreement aims to end costly legal battles and allow both companies to focus on innovation and market growth in the critical heart valve repair sector. While the settlement brings clarity and mitigates future legal risks, it comes with an immediate financial impact. Edwards Lifesciences will recognize a pretax charge of approximately $368 million in the second quarter of 2020. Additionally, the company anticipates incurring royalty expenses totaling around $100 million through May 2024, which will be recorded as a cost of sales. Investors should monitor how these charges affect near-term profitability and the company's cost structure.